Therapeutic Strategies in Huntington's Disease.
This article provides an overview of the therapeutic strategies, from ordinary classical drugs to the modern molecular strategy at experimental level, for Huntington's disease. The disease is characterized by choreic movements, psychiatric disorders, striatal atrophy with selective small neuronal loss, and autosomal dominant inheritance. The genetic abnormality is CAG expansion in huntingtin gene. Mutant huntingtin with abnormally long glutamine stretch aggregates and forms intranuclear inclusions. In this review, I summarize the results of previous trials from the following aspects; 1. symptomatic/palliative therapies including drugs, stereotaxic surgery and repetitive transcranial magnetic stimulation, 2. anti-degenerative therapies including anti-excitotoxicity, reversal of mitochondrial dysfunction and anti-apoptosis, 3. restorative/reparative therapies including neural trophic factors and tissue or stem cell transplantation, and 4. molecular targets in specific and radical therapies including inhibition of truncation of huntingtin, inhibition of aggregate formation, normalization of transcriptional dysregulation, enhancement of autophagic clearance of mutant huntingtin, and specific inhibition of huntingtin expression by sRNAi. Although the strategies mentioned in the latter two categories are mostly at laboratory level at present, we are pleased that one can discuss such "therapeutic strategies", a matter absolutely impossible before the causal gene of Huntington's disease was identified more than 10 years ago. It is also true, however, that some of the "therapeutic strategies" mentioned here would be found difficult to implement and abandoned in the future.
Kanazawa
Ichiro
I
National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
Hum Mol Genet. 2006 Apr 1;15(7):1209-16
16497721
Nat Med. 2000 Jul;6(7):797-801
10888929
Mol Ther. 2005 Oct;12(4):618-33
16019264
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12171-6
14527999
Ann Neurol. 1999 Sep;46(3):366-73
10482267
Cell. 2000 Mar 31;101(1):57-66
10778856
Int Clin Psychopharmacol. 2004 Nov;19(6):337-42
15486519
Cell. 2005 Dec 29;123(7):1241-53
16377565
Biochem Biophys Res Commun. 2006 Apr 28;343(1):190-7
16530728
Ann Neurol. 1978 Sep;4(3):279-84
152602
Mol Med Today. 1997 Apr;3(4):175-83
9134531
Genes Dev. 2001 Jan 15;15(2):188-200
11157775
Trends Neurosci. 2000 Sep;23(9):387-92
10941183
Nature. 1983 Nov 17-23;306(5940):234-8
6316146
Neurology. 1982 Apr;32(4):354-8
6460947
Neurobiol Dis. 2006 Jan;21(1):228-36
16111888
Nat Med. 2002 Feb;8(2):143-9
11821898
Proc Natl Acad Sci U S A. 2002 Dec 10;99 Suppl 4:16400-6
12200548
J Neurosci. 1999 Feb 1;19(3):964-73
9920660
Nature. 2001 Oct 18;413(6857):739-43
11607033
Ann Neurol. 1989 Mar;25(3):252-9
2524992
N Engl J Med. 1973 Feb 15;288(7):337-42
4345566
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):892-7
15642944
Hum Mol Genet. 2000 Aug 12;9(13):2009-18
10942430
Curr Gene Ther. 2006 Feb;6(1):147-59
16475952
NeuroRx. 2004 Oct;1(4):394-405
15717043
Neuroscience. 1985 Dec;16(4):799-817
2936982
Cell Mol Life Sci. 2003 Jul;60(7):1427-39
12943229
Neurology. 2006 Jan 24;66(2):250-2
16434666
Pharmacol Ther. 2005 Nov;108(2):193-207
16055197
Science. 2001 Jul 20;293(5529):493-8
11408619
Nature. 2001 May 24;411(6836):494-8
11373684
Neurology. 2001 Aug 14;57(3):397-404
11502903
J Biol Chem. 1998 Feb 13;273(7):3963-6
9461583
J Neurosci. 2005 Oct 5;25(40):9152-61
16207874
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6
12149470
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4246-51
16537516
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11840-5
16087879
Brain Pathol. 1999 Jan;9(1):147-63
9989457
Hum Mol Genet. 2001 Jun 1;10(12):1307-15
11406612
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5820-5
15811941
Neurology. 2005 Jul 26;65(2):286-92
16043801
Neurology. 1976 Jan;26(1):61-3
128707
Cell. 1997 Aug 8;90(3):537-48
9267033
Neurosci Res. 2005 Nov;53(3):241-9
16095740
Lancet Neurol. 2006 Apr;5(4):303-9
16545746
Science. 1994 Feb 11;263(5148):808-11
8303297
Neurology. 2003 Dec 9;61(11):1551-6
14663041
Arch Neurol. 2003 Jul;60(7):996-8
12873857
Nature. 2002 Jul 11;418(6894):244-51
12110901
Brain. 1980 Mar;103(1):179-210
6102490
Nat Genet. 2004 Jun;36(6):585-95
15146184
Nat Med. 2004 Feb;10(2):148-54
14730359
Nature. 1998 Feb 19;391(6669):806-11
9486653
Cell. 2006 Jun 16;125(6):1179-91
16777606
Neurosci Res. 2005 Jul;52(3):243-9
15896865
Hum Genet. 1996 Dec;98(6):633-5
8931689
Mol Cell Neurosci. 2000 Oct;16(4):313-23
11085870
Exp Neurol. 2005 May;193(1):65-74
15817265
J Neurosci. 2003 Oct 15;23(28):9418-27
14561870
J Cell Biol. 2006 Feb 27;172(5):719-31
16505167
Cell. 1993 Mar 26;72(6):971-83
8458085
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5355-8
8202492
J Neurol Sci. 2005 Apr 15;231(1-2):57-66
15792822
Neurobiol Dis. 2001 Jun;8(3):391-404
11442349
Hum Mol Genet. 2003 May 1;12(9):985-94
12700167
Gene Ther. 2006 Mar;13(6):509-16
16520821
Mol Cell Biol. 1995 Dec;15(12):6804-12
8524246
Curr Pharm Des. 2006;12(21):2701-20
16842168
Hum Mol Genet. 2003 Mar 1;12(5):497-508
12588797
Neurology. 2006 Feb 14;66(3):366-72
16476934
N Engl J Med. 1975 Sep 4;293(10):504-5
125382
Biochem Biophys Res Commun. 2002 Jun 7;294(2):429-40
12051730
Science. 1997 Sep 26;277(5334):1990-3
9302293
Mov Disord. 1994 Mar;9(2):178-82
8196679
J Pharmacol Exp Ther. 2000 Oct;295(1):239-43
10991985
Trends Neurosci. 2001 Mar;24(3):182-8
11182459
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18189-94
16326808
BMC Neurosci. 2005 Jan 13;6:1
15649316
Nature. 2003 Jan 23;421(6921):373-9
12540902
Hum Mol Genet. 2004 Jul 1;13(13):1389-405
15115766
Nature. 2006 May 25;441(7092):537-41
16724069
Neuron. 2003 Nov 13;40(4):685-94
14622574
Ann Neurol. 2005 Oct;58(4):655-6
16178020